| Zhang, Anqin |
TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 970 | RoW | Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin | Shanghai Jiao Tong University School of Medicine | Breast Neoplasm | 12/22 | 12/23 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients |
|
|
| Recruiting | 3 | 688 | RoW | Tamoxifen, Nolvadex, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 05/25 | 05/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04975451: ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | Anlotinib | Anqin Zhang | Breast Cancer | 05/24 | 05/24 | | |
